Yescarta

FDA

drug manufacturing

relapsed or refractory large B-cell lymphoma

Kite publishes Phase II data for Yescarta in treating B-cell lymphoma

Clinical Trials Arena

Mon, 09/18/23 - 09:53 am

Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma

Businesswire

Tue, 06/6/23 - 10:11 am

relapsed or refractory large B-cell lymphoma

Gilead’s Yescarta extends survival in lymphoma study

BioPharma Dive

Tue, 03/21/23 - 09:53 pm

large B-cell lymphoma

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

Fierce Pharma

Thu, 01/26/23 - 10:40 am

Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences

NASDAQ.com

Thu, 12/8/22 - 10:03 am

Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers

Fierce Pharma

Mon, 11/7/22 - 05:48 pm

Gilead's Yescarta eyes first to move up lymphoma ladder in Europe amid busy week at EMA

Fierce Pharma

Mon, 09/19/22 - 09:12 am

diffuse large B-cell lymphoma

Europe

high-grade B-cell lymphoma

Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead

Biopharma Reporter

Wed, 04/20/22 - 10:43 am

Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030

Fierce Pharma

Mon, 04/18/22 - 11:47 pm

Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst

Fierce Pharma

Thu, 12/16/21 - 11:57 pm

ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma

Fierce Pharma

Sat, 12/11/21 - 09:22 pm

What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More

OBR Oncology

Wed, 11/24/21 - 10:23 am

New fault lines emerge in CAR-T therapy

EP Vantage

Tue, 08/24/21 - 10:43 am

Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients

Endpoints

Mon, 06/28/21 - 10:51 am

relapsed or refractory diffuse large B-cell lymphoma

#ASCO21: Novartis gears up for CAR-T fight with Gilead in follicular lymphoma — and safety could define the battle

Endpoints

Thu, 06/3/21 - 10:51 am

Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting

Biopharma Reporter

Wed, 04/7/21 - 07:13 pm

ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy

Fierce Pharma

Tue, 12/8/20 - 12:07 am

diffuse large B-cell lymphoma

clinical trials

Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas

MedCity News

Tue, 09/8/20 - 10:40 am

follicular lymphoma

marginal zone lymphoma

ASCO 2020